Evotec SEEVO +1.11%64 Market Cap is $973.2 Mil as of Jun. 27, 2026. GuruFocus rates EVO with a GF Score™ of 64/100 and a GF Value™ of $4.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Evotec SE ranks better than 75.66% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Evotec SE's share price for the quarter that ended in Mar. 2026 was $2.5. Evotec SE's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 355.2 Mil. Therefore, Evotec SE's market cap for the quarter that ended in Mar. 2026 was $888.0 Mil.
Evotec SE's quarterly market cap
declined
from Sep. 2025 ($1,289.4 Mil) to Dec. 2025 ($1,093.2 Mil) and
declined
from Dec. 2025 ($1,093.2 Mil) to Mar. 2026 ($888.0 Mil).
Evotec SE's annual market cap
declined
from Dec. 2023 ($4,156.8 Mil) to Dec. 2024 ($1,477.2 Mil) and
declined
from Dec. 2024 ($1,477.2 Mil) to Dec. 2025 ($1,093.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Evotec SE's Enterprise Value for Today is $884.9 Mil.
Evotec SE (NAS:EVO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Evotec SE Market Cap Related Terms
Evotec SE Market Cap Historical Data
* Premium members only.
The historical data trend for Evotec SE's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Market Cap distribution charts can be found below:
* The bar in red indicates where Evotec SE's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Evotec SE's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (EVO) has a Market Cap of $973.2 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #249 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 24.3%.
Is Evotec SE's Market Cap too high?
Evotec SE's current Market Cap is $973.2 Mil. The Drug Manufacturers industry median Market Cap is 205.37. Evotec SE's value of $973.2 Mil is 373.9% above this industry median. Based on the distribution chart, Evotec SE ranks #249 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Evotec SE has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #249 out of 1023 companies for Market Cap. This places Evotec SE in the top 24% of its industry — outperforming the majority of peers. The industry median Market Cap is 205.37. Evotec SE's value of $973.2 Mil is 373.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current Market Cap of $973.2 Mil is 373.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Market Cap is $973.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.26, compared to a current price of $2.74 — trading 35.7% below its estimated fair value. The current Market Cap is $973.2 Mil and 373.9% above the Drug Manufacturers industry median of 205.37. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Evotec SE (EVO), the current Market Cap is $973.2 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVO) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $2.74 is trading 35.7% below its estimated GF Value™ of $4.26.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVO:
Market Cap: $973.2 Mil
GF Value™: $4.26 vs. price of $2.74 (35.7% below fair value)
Industry Position: 373.9% above the Drug Manufacturers median (#249 of 1023)
No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score
Get the complete analysis for EVO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVO has been successfully added to your 
